高流量鼻导管与低水平持续气道正压在新发急性低氧性呼吸衰竭中具有不同的生理效应
这项前瞻性单中心研究纳入29例接受HFNC(50–60 L·min⁻¹)的新发AHRF患者,用电阻抗断层成像先后监测HFNC和CPAP 4 cmH2O下的生理指标。HFNC下潮气量为6.6(5.9–8.7)mL·kg⁻¹ PBW,20例(69%)在4–8 mL·kg⁻¹ PBW之间,5例(17%)超过9 mL·kg⁻¹ PBW;CPAP下潮气量更高,为9.4(8.3–11)mL·kg⁻¹ PBW(p<0.001),两者仅中度相关(Spearman r=0.50,p=0.005),Bland-Altman偏倚2.4 mL·kg⁻¹,一致性界限-1.1至5.9 mL·kg⁻¹。低水平CPAP下潮气量>11.5 mL·kg⁻¹ PBW可预测HFNC下潮气量>9 mL·kg⁻¹ PBW,敏感性80%、特异性96%。CPAP还增加分钟通气量、呼气末肺容积和氧合,在病情最重患者中减轻呼吸窘迫征象,但舒适度低于HFNC。作者结论认为HFNC下潮气量多为保护性,CPAP 4 cmH2O不能预测HFNC下潮气量。
要点
- HFNC(50–60 L·min⁻¹)下潮气量为6.6(5.9–8.7)mL·kg⁻¹ PBW,20例(69%)在4–8 mL·kg⁻¹ PBW之间,5例(17%)超过9 mL·kg⁻¹ PBW。
- CPAP 4 cmH2O下潮气量高于HFNC,为9.4(8.3–11)mL·kg⁻¹ PBW(p<0.001),两者仅中度相关(Spearman r=0.50,p=0.005)。
- Bland-Altman分析显示CPAP与HFNC潮气量偏倚2.4 mL·kg⁻¹,一致性界限-1.1至5.9 mL·kg⁻¹,CPAP潮气量不能预测HFNC潮气量。
- 低水平CPAP下潮气量>11.5 mL·kg⁻¹ PBW预测HFNC下潮气量>9 mL·kg⁻¹ PBW的敏感性80%、特异性96%。
- 与HFNC相比,CPAP 4 cmH2O增加分钟通气量、呼气末肺容积和氧合,在病情最重患者中减轻呼吸窘迫征象,但舒适度更低。
适用人群与场景
- 新发急性低氧性呼吸衰竭(de novo AHRF)的ICU患者,共29例,接受HFNC(50–60 L·min⁻¹)治疗。
处置流程与药物剂量
- HFNC设置流量50–60 L·min⁻¹;CPAP设置4 cmH2O。
- 研究顺序为先HFNC后CPAP 4 cmH2O,均用电阻抗断层成像监测。
研究设计与关键结果
- 前瞻性单中心研究,纳入29例新发AHRF患者,HFNC(50–60 L·min⁻¹)下用电阻抗断层成像测潮气量,随后CPAP 4 cmH2O下监测。
- HFNC下潮气量6.6(5.9–8.7)mL·kg⁻¹ PBW;20例(69%)潮气量在4–8 mL·kg⁻¹ PBW,5例(17%)超过9 mL·kg⁻¹ PBW。
- CPAP下潮气量高于HFNC,为9.4(8.3–11)mL·kg⁻¹ PBW(p<0.001);两者中度相关(Spearman r=0.50,p=0.005)。
- Bland-Altman分析偏倚2.4 mL·kg⁻¹,一致性界限-1.1至5.9 mL·kg⁻¹。
- CPAP下潮气量>11.5 mL·kg⁻¹ PBW预测HFNC下潮气量>9 mL·kg⁻¹ PBW,敏感性80%、特异性96%。
- 与HFNC相比,CPAP 4 cmH2O增加分钟通气量、呼气末肺容积和氧合,在病情最重患者中减轻呼吸窘迫征象,但舒适度更低。
证据类型、等级与局限
- 前瞻性单中心生理学研究,样本量29例。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在新发AHRF的ICU患者中,HFNC下潮气量大多为保护性。
- 作者结论认为,CPAP 4 cmH2O下潮气量不能预测HFNC下潮气量;这种低水平CPAP与潮气量、分钟通气量、呼气末肺容积和氧合增加相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Large tidal volumes during de novo acute hypoxemic respiratory failure (AHRF) may promote patient self-inflicted lung injury. Tidal volume assessment under high flow nasal cannula (HFNC) is not routinely feasible at the bedside. Our objective was to determine whether tidal volume during low-level continuous positive airway pressure (CPAP) could predict tidal volume during HFNC and to compare the physiological effects of HFNC and low-level CPAP.
METHODS: Prospective, single-center study including 29 de novo AHRF patients treated with HFNC (50 to 60 L.min- 1). Patients were monitored using electrical impedance tomography during HFNC then CPAP at 4 cmH2O. Tidal volume during HFNC was calculated based on tidal impedance variation. The ability of tidal volume under low-level CPAP to predict tidal volume under HFNC was explored using Bland-Altman analysis. CPAP and HFNC were compared in terms of tidal volume, minute ventilation, respiratory comfort, dyspnea, oxygenation, ventilation distribution, end-expiratory lung volume, thoraco-abdominal asynchrony and recruitment.
RESULTS: Under HFNC, patients had a tidal volume of 6.6 (5.9-8.7) mL.kg- 1 PBW. 20 (69%) patients exhibited a tidal volume between 4 and 8 mL.kg- 1 PBW, while in 5 (17%) patients it exceeded 9 mL.kg- 1 PBW. Tidal volume under CPAP was higher (9.4 (8.3-11) mL.kg- 1 PBW, p < 0.001). Tidal volumes under CPAP and under HFNC were modestly correlated (Spearman r = 0.50, p = 0.005). Bland-Altman analysis showed a bias of 2.4 mL.kg- 1, with limits of agreement ranging from - 1.1 mL.kg- 1to 5.9 mL.kg- 1. Nevertheless, a larger (> 11.5 mL.kg- 1 PBW ) tidal volume under low-level CPAP predicted a larger (> 9 mL.kg- 1 PBW ) tidal volume under HFNC with 80% sensitivity and 96% specificity. Low-level CPAP was associated with increased minute ventilation, end-expiratory lung volume, and oxygenation as compared to HFNC. It decreased signs of respiratory distress in the most severe patients but was associated with lower comfort compared to HFNC.
CONCLUSION: Among ICU patients with de novo AHRF, tidal volume under HFNC was mostly protective. Tidal volume during CPAP at 4 cmH2O did not predict tidal volume during HFNC. Such low-level CPAP was associated with increased tidal volume, minute ventilation, end-expiratory volume, and oxygenation.
TRIAL REGISTRATION: ClinicalTrials.gov ID NCT03919331. Registration date: 2019-03-26.
参考来源
- Tuffet S, Boujelben MA, Haudebourg AF, et al. High flow nasal cannula and low level continuous positive airway pressure have different physiological effects during de novo acute hypoxemic respiratory failure. Ann Intensive Care. 2024. PMID: 39578265. doi:10.1186/s13613-024-01408-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。